[Treatment of neuropathic pain syndrome. Results of an open study on the efficacy of a pyrimidine nucleotide preparation]. / Therapie des neuropathischen Schmerzsyndroms. Ergebnisse einer offenen Studie zur Wirksamkeit eines Pyrimidinnukleotid-Präparats.

BACKGROUND AND METHOD: In a study carried out in the years 2000 and 2002, 40 patients with diabetic polyneuropathy were treated with a daily dose of 2 x 2 capsules of the pyrimidine nucleotide preparation, Keltican N for a period of three months. The structured neurological findings in accordance with the Neuropathy Disability Score (NDS), the conduction velocity of the peroneal and sural nerves, and pain sensation on the basis of a visual analog scale. RESULTS: All parameters showed a trend towards improvement. The difference in the sensory conduction velocity of the sural nerve and in the subjective pain score was significant.

Structural determinants of HIV-1 reverse transcriptase stereoselectivity towards (beta)-L-deoxy- and dideoxy-pyrimidine nucleoside triphosphates: molecular basis for the combination of L-dideoxynucleoside analogs with non-nucleoside inhibitors in anti HIV chemotherapy.

We have compared the HIV-1 RT mutants containing the single substitutions L100I, K103N, V106A, V179D, Y181I and Y188L, known to confer NNI-resistance in treated patients, to HIV-1 RT wt for their sensitivity towards inhibition by D- and L-deoxy- and dideoxy-nucleoside tiphosphates. The results showed a differential effect of the substitutions on the affinity for both D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphates and provide a rationale for the utilization of L-dideoxynucleoside analogs with NNI in combination chemotherapy.